Related Experiment Video
Updated: May 21, 2025
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Outcome Of Gpllb/Llla Inhibitors In Totally Occluded Coronary Artery In Patients Presenting With Acute Myocardial
Fahad Khalid1, Muhammad Fareed Khan2, Wahab Anwar3
1NUST School of Health Sciences, Islamabad-Pakistan.
Insights
Glycoprotein IIb/IIIa inhibitors show promise in treating acute myocardial infarction (AMI) in Pakistani patients presenting late for treatment. While reducing adverse cardiac events, careful patient selection is vital due to increased bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Acute coronary ischemia, particularly acute myocardial infarction (AMI) from occluded arteries, carries high mortality.
- The study addresses the use of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors in Pakistani patients with delayed presentation for reperfusion therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of GP IIb/IIIa inhibitors in Pakistani patients with AMI presenting late for primary percutaneous coronary intervention (PCI) or thrombolysis.
- To assess the impact of GP IIb/IIIa inhibitors on major adverse cardiac events (MACE), recurrent myocardial infarction (MI), thrombus resolution, and myocardial salvage.
Main Methods:
- A trial involving 200 patients was conducted at a tertiary care hospital in Islamabad.
- GP IIb/IIIa inhibitors were administered to 40% of patients with infarct-related artery (IRA) cases.
Main Results:
- GP IIb/IIIa inhibitors demonstrated a 9% reduction in MACE, 7.5% reduction in recurrent MI, 25% improvement in thrombus resolution, and 12% increase in myocardial salvage.
- A statistically significant increase in bleeding complications was observed (p<.05).
- No significant differences were found in in-hospital mortality, length of stay, or renal complications.
Conclusions:
- GP IIb/IIIa inhibitors are not universally indicated and require careful patient selection and monitoring.
- Dose-adjusted infusion regimens of Eptifibatide or Tirofiban are crucial for managing coagulation levels.
- Further large-scale, multicenter studies are necessary to confirm long-term safety and efficacy, especially in regions with limited advanced cardiac care access.
Background:
Acute coronary ischemia is one of the most fatal cardiovascular events, presenting with tremendously high morbidity and mortality, especially in cases involving a completely occluded artery, leading to acute myocardial infarction (AMI). The study aimed to ascertain the efficacy and safety of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors in Pakistani patients who present late for thrombolysis or primary percutaneous coronary intervention (PCI).
Methods:
The trial was conducted at a tertiary care hospital in Islamabad, including 200 patients, with GP IIb/IIIa inhibitors used in 40% of infarct-related artery (IRA) cases.
Results:
The analysis revealed that GP IIb/IIIa inhibitors reduced major adverse cardiac events (MACE) by 9%, recurrent myocardial infarction (MI) by 7.5%, and improved thrombus resolution by 25%, as well as myocardial salvage by 12%. However, there was a higher rate of bleeding complications (p<.05) associated with their use. No other significant adverse events, such as in-hospital mortality, length of stay, or renal complications, were identified.
Conclusions:
These results suggest that GP IIb/IIIa inhibitors should not be used as a one-size-fits-all therapy. Proper patient selection, along with robust monitoring under dose-adjusted Eptifibatide or Tirofiban infusion regimens to target coagulation levels appropriately, is crucial. Although this treatment could be valuable in managing AMI, particularly in regions where advanced cardiac care is less accessible, further large-scale, multicenter studies are needed to determine its long-term safety and efficacy. This study provides a framework for further investigations into the use of GP IIb/IIIa inhibitors in similar patient populations.
